Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Immune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overa...

Full description

Bibliographic Details
Main Authors: Haoxin Li, Kevin Bullock, Carino Gurjao, David Braun, Sachet A. Shukla, Dominick Bossé, Aly-Khan A. Lalani, Shuba Gopal, Chelsea Jin, Christine Horak, Megan Wind-Rotolo, Sabina Signoretti, David F. McDermott, Gordon J. Freeman, Eliezer M. Van Allen, Stuart L. Schreiber, F. Stephen Hodi, William R. Sellers, Levi A. Garraway, Clary B. Clish, Toni K. Choueiri, Marios Giannakis
Format: Article
Language:English
Published: Nature Publishing Group 2019-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-12361-9
id doaj-e4c8bc25921749a9be4db41b69a5d41b
record_format Article
spelling doaj-e4c8bc25921749a9be4db41b69a5d41b2021-05-11T11:48:26ZengNature Publishing GroupNature Communications2041-17232019-09-011011610.1038/s41467-019-12361-9Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li0Kevin Bullock1Carino Gurjao2David Braun3Sachet A. Shukla4Dominick Bossé5Aly-Khan A. Lalani6Shuba Gopal7Chelsea Jin8Christine Horak9Megan Wind-Rotolo10Sabina Signoretti11David F. McDermott12Gordon J. Freeman13Eliezer M. Van Allen14Stuart L. Schreiber15F. Stephen Hodi16William R. Sellers17Levi A. Garraway18Clary B. Clish19Toni K. Choueiri20Marios Giannakis21Department of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardBristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbDepartment of Medical Oncology, Dana-Farber Cancer InstituteBeth Israel Deaconess Medical CenterDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteImmune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overall survival.https://doi.org/10.1038/s41467-019-12361-9
collection DOAJ
language English
format Article
sources DOAJ
author Haoxin Li
Kevin Bullock
Carino Gurjao
David Braun
Sachet A. Shukla
Dominick Bossé
Aly-Khan A. Lalani
Shuba Gopal
Chelsea Jin
Christine Horak
Megan Wind-Rotolo
Sabina Signoretti
David F. McDermott
Gordon J. Freeman
Eliezer M. Van Allen
Stuart L. Schreiber
F. Stephen Hodi
William R. Sellers
Levi A. Garraway
Clary B. Clish
Toni K. Choueiri
Marios Giannakis
spellingShingle Haoxin Li
Kevin Bullock
Carino Gurjao
David Braun
Sachet A. Shukla
Dominick Bossé
Aly-Khan A. Lalani
Shuba Gopal
Chelsea Jin
Christine Horak
Megan Wind-Rotolo
Sabina Signoretti
David F. McDermott
Gordon J. Freeman
Eliezer M. Van Allen
Stuart L. Schreiber
F. Stephen Hodi
William R. Sellers
Levi A. Garraway
Clary B. Clish
Toni K. Choueiri
Marios Giannakis
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Nature Communications
author_facet Haoxin Li
Kevin Bullock
Carino Gurjao
David Braun
Sachet A. Shukla
Dominick Bossé
Aly-Khan A. Lalani
Shuba Gopal
Chelsea Jin
Christine Horak
Megan Wind-Rotolo
Sabina Signoretti
David F. McDermott
Gordon J. Freeman
Eliezer M. Van Allen
Stuart L. Schreiber
F. Stephen Hodi
William R. Sellers
Levi A. Garraway
Clary B. Clish
Toni K. Choueiri
Marios Giannakis
author_sort Haoxin Li
title Metabolomic adaptations and correlates of survival to immune checkpoint blockade
title_short Metabolomic adaptations and correlates of survival to immune checkpoint blockade
title_full Metabolomic adaptations and correlates of survival to immune checkpoint blockade
title_fullStr Metabolomic adaptations and correlates of survival to immune checkpoint blockade
title_full_unstemmed Metabolomic adaptations and correlates of survival to immune checkpoint blockade
title_sort metabolomic adaptations and correlates of survival to immune checkpoint blockade
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2019-09-01
description Immune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overall survival.
url https://doi.org/10.1038/s41467-019-12361-9
work_keys_str_mv AT haoxinli metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT kevinbullock metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT carinogurjao metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT davidbraun metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT sachetashukla metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT dominickbosse metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT alykhanalalani metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT shubagopal metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT chelseajin metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT christinehorak metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT meganwindrotolo metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT sabinasignoretti metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT davidfmcdermott metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT gordonjfreeman metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT eliezermvanallen metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT stuartlschreiber metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT fstephenhodi metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT williamrsellers metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT leviagarraway metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT clarybclish metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT tonikchoueiri metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
AT mariosgiannakis metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade
_version_ 1721446014666145792

Similar Items